 |
|
|
| |
BMS-955176: Antiviral Activity and Safety of a Second-Generation HIV-1 Maturation Inhibitor
|
| |
| |
Reported by Jules Levin
CROI 2015 Feb 23-26 Seattle, WA
Carey Hwang,1 Dirk Schurmann,2 Christian Sobotha,2 Heather Sevinsky,1
Palanikumar Ravindran,1 Hong Xiao,1 Neelanjana Ray,1 Mark Krystal,3 Ira Dicker3 and Max Lataillade3, on behalf of the BMS HIV Development Team
1 Bristol-Myers Squibb, Research and Development, Princeton, NJ, USA
2 Charite Research Organisation GmbH, Chariteplatz 1, 10117 Berlin, Germany
3 Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA
Webcast
http://www.croiwebcasts.org/console/player/25756?mediaType=slideVideo&
|
| |
|
|
|
|
|
